

BUYINS.NET

DIRECTOR OF RESEARCH: Thomas Ronk PH (800) 715-9999 EMAIL: tom@buyins.net DATE: 7-15-2005

INSIDE THIS ISSUE:

MNTA 1

About Us 2

RECENT HEADLINES

07-15-2005 12:24
BUYINS.NET: AVNC, DCTH, ENY, LFC, MNTA, WHAI Have Been On ...

07-05-2005 08:00 StreetInsider Alert for MNTA

06-28-2005 09:37
BUYINS.NET: MEND, MNTA, PORK, WHAI, MDVN have also been added ...

06-28-2005 07:52 MNTA: To Present At Bear Stearns Biotech Conference @ 07:30 ...

06-24-2005 11:29 Momenta Pharmaceuticals to Present at the Bear Stearns Boston Biotech Conference

06-23-2005 11:47 WallStreetGrapevine: "Stocks on the Rise"

06-23-2005 10:51 StreetInsider.com: Stock Movers of Note 06/23

BUYINS.NET offers a proprietary research and trading service uncovering illegal naked short selling in stocks on the NYSE, AMEX, NASDAQ, OTCBB and PINKSHEETS. For more information please visit www.buyins.net

MNTA RUNNING HARD

On June 28th, Buyins.net announced that Momenta Pharmaceuticals (NASDAQ: MNTA) had been added to the NASDAQ Naked Short Threshold List. The stock opened the day at \$20.35 and has jumped to an intraday price as high as \$34.60 today. Buyins.net announced today that MNTA had now been on the Naked Short List for 13 straight days. The stock jumped over \$11 points in one day!



Omnitrading advisor issued a buy recommendation at \$16.50. MNTA has absolutely exploded since it has been on the NASDAQ Naked Short List.

FUNDAMENTAL HIGHLIGHTS AT MNTA

On June 16th it was confirmed that MNTA is developing a generic version of Lovonex. Shares continue to mover higher after Sanofi (SNY) said it intends to appeal against Wednesday's preliminary U.S. court

ruling in favor of the generic drug manufacturer's planning to copy its anti-thrombotic medication Lovonex. If confirmed by the California court handling the case, the ruling would result in the lifting of the 30-month

stay period during which the two generic drug makers cannot launch their products on the market. Lovonex is one of Sanofi's best-selling drugs.

WWW.BUYINS.NET

417 Orchid Ave.
Corona Del Mar, CA 92625

Phone: 800-715-9999
Fax: 815-328-0698

Email: tom@buyins.net

Trading Solutions to Naked Short Selling

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.

BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.

BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment.

All Rights Reserved. Copyright 2005 Buyins.net

REVERSE ENGINEERING TODAY'S TOP GAINERS FOR TOMORROW'S BIG WINNERS

Share Statistics

Average Volume (3 month):	484,182
Average Volume (10 day):	826,600
Shares Outstanding:	25.50M
Float:	16.77M
% Held by Insiders:	14.54%
% Held by Institutions:	15.60%
Shares Short (as of 10-Jun-05):	241.22K
Short Ratio (as of 10-Jun-05):	3.7
Short % of Float (as of 10-Jun-05):	1.20%
Shares Short (prior month):	208.39K

Momenta Pharmaceuticals has been on the NASDAQ naked short list for 13 consecutive trading day. Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. Regulation SHO mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.

The short position in shares of MNTA has not grown much from May to June. Currently, there are 241,220 shares declared short as of June 10th. While there is a failure to deliver in shares of MNTA, it is unclear to what extent that failure will cause further upside bias in the stock.



This intraday chart of MNTA on July 15th shows a dramatic increase in volume and price.